Tesamorelin: what it is and what the evidence says
A GHRH analog that stimulates the pituitary to release growth hormone in pulses and is associated with visceral-fat reduction in clinical studies. It is FDA-approved for excess abdominal fat in adults with HIV and lipodystrophy.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Visceral fat, body composition.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
Two randomized, double-blind, placebo-controlled phase 3 trials in more than 800 people with HIV and lipodystrophy showed a reproducible reduction in visceral abdominal fat of about 15% versus placebo. Two later trials in people with HIV showed less liver fat, and there are smaller trials in abdominal obesity and in cognition in older adults.
The limitation that matters most
Its cardiovascular safety and the effects of keeping IGF-1 elevated over the very long term are still unknown, and there are almost no data in healthy people or in people without HIV. The effect on visceral fat reverses when treatment stops, and it can raise blood glucose, so it requires follow-up.
Regulatory status
FDA-approved since 2010 (Egrifta, and since 2025 Egrifta WR) to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not indicated for weight loss, and in Europe the application was withdrawn in 2012. Prohibited at all times in sport by WADA (section S2, GHRH analogs).
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
It acts on the growth-hormone axis, raises IGF-1, and can raise blood glucose, so both are measured before and during use. It is contraindicated in pregnancy, with active cancer, and when the pituitary is damaged.
It is assessed with a doctor before starting and throughout use, especially with diabetes, a history of cancer, or glucocorticoid treatment.
What this page cannot give you
A reference page can take you this far. You know what Tesamorelin is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Metabolic effects of a growth hormone-releasing factor in patients with HIVhuman N Engl J Med · 2007 · PMID 18057338 →
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionhuman J Acquir Immune Defic Syndr · 2010 · PMID 20101189 →
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab · 2010 · PMID 20554713 →
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationhuman AIDS · 2008 · PMID 18690162 →
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialhuman Lancet HIV · 2019 · PMID 31611038 →
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLDhuman JCI Insight · 2020 · PMID 32701508 →
- Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelinhuman Clin Infect Dis · 2012 · PMID 22495074 →
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophyreview Drugs · 2011 · PMID 21668043 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Tesamorelin or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Tesamorelin?
A GHRH analog that stimulates the pituitary to release growth hormone in pulses and is associated with visceral-fat reduction in clinical studies. It is FDA-approved for excess abdominal fat in adults with HIV and lipodystrophy. It is studied within the area of metabolic.
Is there human evidence for Tesamorelin?
Two randomized, double-blind, placebo-controlled phase 3 trials in more than 800 people with HIV and lipodystrophy showed a reproducible reduction in visceral abdominal fat of about 15% versus placebo. Two later trials in people with HIV showed less liver fat, and there are smaller trials in abdominal obesity and in cognition in older adults.
Is it approved by any health agency?
FDA-approved since 2010 (Egrifta, and since 2025 Egrifta WR) to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not indicated for weight loss, and in Europe the application was withdrawn in 2012. Prohibited at all times in sport by WADA (section S2, GHRH analogs).
What is the dose of Tesamorelin?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Tesamorelin is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.